Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JOINT-07 abaloparatide vs alendronate in high-fracture-risk osteoporosis
jRCTs031250016Recruiting
- Sponsor
- Teijin Pharma
- Start
- May 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Randomised trial in involutional osteoporosis comparing Abaloparatide group with Alendronate group (2 arms). Primary endpoint: Change of bone strength in femoral and vertebral bone at 78 weeks. Started May 2025; status: recruiting.
02
Drugs
abaloparatidealendronate
03
Conditions
involutional osteoporosis
Beyond the preview
Go deeper on jRCTs031250016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250016.